After a treatment with dapagliflozin at 10 mg, there remains at least ~8–10% of residual SGLT2 activity, i.e., 7–11 mmol/h of reabsorption rate, in the healthy and diabetics. The gene discussed is SLC5A2; the disease is diabetes mellitus.